Welcome to our dedicated page for Zealand Pharma A/S news (Ticker: ZEAL), a resource for investors and traders seeking the latest updates and insights on Zealand Pharma A/S stock.
News about Zealand Pharma A/S (Nasdaq: ZEAL) centers on its work as a biotechnology company focused on peptide-based medicines for obesity and metabolic health, as well as its collaborations, clinical data and capital markets activity. Company announcements and partner press releases highlight progress across clinical trials, strategic agreements and shareholder developments.
Readers following ZEAL news will find updates on clinical programs such as BI 456906, a dual glucagon/GLP‑1 receptor agonist co‑invented with Boehringer Ingelheim. Phase II trial results reported by Boehringer Ingelheim and Zealand Pharma showed dose‑dependent weight loss in people living with obesity or overweight and in people with type 2 diabetes, reflecting the company’s focus on metabolic pathways. News also covers scientific presentations at major meetings, where Zealand Pharma shares preclinical and clinical data on investigational peptide candidates including dapiglutide, ZP8396 and ZP6590 for potential obesity and metabolic indications.
Another recurring news theme is strategic collaboration. For example, Zealand Pharma and OTR Therapeutics announced a multi‑program strategic collaboration and license agreement to discover and develop novel therapeutics for multiple targets in metabolic diseases. Under this agreement, OTR Therapeutics leads research and preclinical development using its proprietary discovery platform, while Zealand Pharma is responsible for clinical development, regulatory submissions and global commercialization.
Investors can also track company announcements on directed share offerings, private placements, capital increases and major shareholder notifications, which explain how Zealand Pharma raises funds to support its pipeline and disclose changes in ownership stakes. For ongoing insight into ZEAL’s clinical progress, partnerships and corporate actions, this news feed aggregates relevant releases and partner communications in one place.
Zealand Pharma has announced amendments to its Articles of Association following the granting of employee warrants. The company aims to attract and retain top talent through this incentive scheme, aligning interests of management, employees, and shareholders. The related share capital increase has been officially registered with the Danish Business Authority. Zealand Pharma, based in Copenhagen, has a focus on innovative peptide-based medicines, with several drug candidates in clinical development and collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals.
Zealand Pharma announced the granting of warrants and restricted share units (RSUs) to employees as part of its incentive programs. A total of 63,217 warrants were issued, representing 0.2% of outstanding shares, with an exercise price of DKK 216.80. The RSU program aims to align management interests with shareholder value, with an estimated value of DKK 1.3 million.
The grants will vest over three years and are intended to enhance employee retention and motivation.
Zealand Pharma has increased its share capital by DKK 13,851 through the exercise of employee warrants, resulting in the issuance of 13,851 new shares. The exercise prices were DKK 135.30 for 2,976 shares and DKK 142.45 for 10,875 shares, generating total proceeds of approximately DKK 1.95 million. Following this increase, Zealand's total share capital will amount to DKK 39,778,961, comprised of 39,778,961 shares. Each new share grants rights to dividends and voting at general meetings.
Zealand Pharma has appointed Dr. Danilo Verge as Head of Global Medical Affairs and Dr. David Kendall as Senior Global Medical Advisor, enhancing its Medical Affairs organization. These seasoned experts, with decades of experience in diabetes, will drive global medical activities related to Zealand's metabolic and gastrointestinal franchises, including dasiglucagon and glepaglutide. The company anticipates launching HypoPal in the U.S. next year, marking a critical phase in its growth.
Zealand Pharma (Nasdaq: ZEAL) announced its participation in four virtual investor conferences in September 2020. Key events include Citi's 15th Annual BioPharma Virtual Conference on September 9, Goldman Sachs Annual Biotech Symposium on September 11, and Morgan Stanley Global Healthcare Conference on September 14, featuring a fireside chat at 10:30 a.m. ET. Zealand will also present at the Økonomisk Ugebrev Life Science Investor Konference on September 23. An archived webcast of the Goldman Sachs event will be available on their website.
Zealand Pharma has reported the total number of shares and voting rights as of August 31, 2020, following a recent increase in share capital due to employee warrant exercises. The total number of shares stands at 39,765,110, with an equivalent share capital amount. Zealand continues to focus on developing innovative peptide-based medicines for metabolic and gastrointestinal diseases, boasting a pipeline of candidates in various stages of clinical development.
Zealand Pharma announced a share capital increase of DKK 30,959 through the exercise of employee warrants. A total of 30,959 new shares were issued at exercise prices of DKK 135.30, DKK 142.45, and DKK 138.6, yielding total proceeds of DKK 4,319,214.90. After the registration with the Danish Business Authority, Zealand's new share capital will stand at DKK 39,765,110. The new shares confer rights to dividends and one vote each at general meetings. Zealand continues to advance its pipeline of peptide-based medicines, with several candidates in clinical development.
Zealand Pharma (Nasdaq: ZEAL) announced its interim report for H1 2020, showing significant developments including a completed acquisition of Valeritas to accelerate U.S. operations, and FDA acceptance of the NDA for dasiglucagon's HypoPal® rescue pen. Total revenue reached DKK 233.4 million, up from DKK 19.9 million in H1 2019. However, net operating expenses surged to DKK 437.2 million. The company raised DKK 657.7 million through a private placement, supporting continued growth and clinical trials. Zealand anticipates net product revenue from V-Go® device sales between DKK 150-175 million for 2020.